TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · major macro event coming up
LYEL

Lyell Immunopharma Inc

Healthcare · Biotechnology

9.80$ +1.7% vs. previous close Closing price · As of: Sep 30, 2026

Statements

Income Statement

Lyell Immunopharma Inc (LYEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 0.0 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement LYEL
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5.1 5.1 5.0 4.9 – 5.0 – 3.1 – 2.4 2.3 – –
-5.1 -5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -2.3 0.0 -2.3
40 42 43 40 40 49 43 35 28 52 37 40 156
16 13 13 12 12 15 14 9.8 11 11 9.6 9.6 40
55 55 56 52 51 201 57 47 37 61 44 47 190
-61 -60 -56 -52 -51 -201 -57 -47 -37 -61 -46 -47 -192
-51 -53 -61 -46 -45 -192 -52 -43 -39 -141 -24 -45 -248
-6.6 5.0 5.0 – – – – – – – – – –
-51 -53 -61 -46 -45 -192 -52 -43 -39 -141 -24 -45 -248
-46 -48 -56 -41 -40 -58 -49 -43 -36 -138 -22 -43 -239

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?